Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients.

Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, Enk AH, Hassel JC.

Immunotherapy. 2019 Jun;11(8):667-676. doi: 10.2217/imt-2018-0146.

PMID:
31088239
2.

Subcutaneous endometriosis mimicking melanoma metastasis.

Buder-Bakhaya K, Hakim-Meibodi LE, Mokry T, Winkler JK, Toberer F, Enk A, Hassel JC.

J Dtsch Dermatol Ges. 2019 Apr 17. doi: 10.1111/ddg.13837. [Epub ahead of print] No abstract available.

PMID:
30994247
3.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
4.

Susceptibility-weighted imaging in malignant melanoma brain metastasis.

Schwarz D, Niederle T, Münch P, Hielscher T, Hassel JC, Schlemmer HP, Platten M, Winkler F, Wick W, Heiland S, Delorme S, Bendszus M, Bäumer P, Breckwoldt MO.

J Magn Reson Imaging. 2019 Feb 21. doi: 10.1002/jmri.26692. [Epub ahead of print]

PMID:
30793419
5.

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F.

Eur J Cancer. 2019 Mar;110:11-20. doi: 10.1016/j.ejca.2018.12.023. Epub 2019 Feb 7.

6.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
7.

18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.

Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC.

Melanoma Res. 2019 Apr;29(2):178-186. doi: 10.1097/CMR.0000000000000541.

PMID:
30653029
8.

Diet-dependent toxicity of ipilimumab in metastatic melanoma.

Majenka P, Hoffmann M, Rötzer I, Dimitrakopoulou-Strauss A, Koschny R, Longerich T, Enk A, Hassel JC.

Eur J Cancer. 2019 Jan;106:220-224. doi: 10.1016/j.ejca.2018.10.018. Epub 2018 Dec 5. No abstract available.

PMID:
30528806
9.

Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?

Sachpekidis C, Larribère L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A.

Cancer Immunol Immunother. 2019 Feb;68(2):297-303. doi: 10.1007/s00262-018-2279-9. Epub 2018 Nov 26.

PMID:
30478475
10.

Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.

Menzer C, Beedgen B, Rom J, Duffert CM, Volckmar AL, Sedlaczek O, Richtig E, Enk A, Jäger D, Hassel JC.

Eur J Cancer. 2018 Nov;104:239-242. doi: 10.1016/j.ejca.2018.09.008. Epub 2018 Oct 25. No abstract available.

PMID:
30454709
11.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514. [Epub ahead of print]

PMID:
30422243
12.

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data.

Soldatos TG, Dimitrakopoulou-Strauss A, Larribere L, Hassel JC, Sachpekidis C.

Diagnostics (Basel). 2018 Oct 31;8(4). pii: E76. doi: 10.3390/diagnostics8040076.

13.

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.

Smetanay K, Junio P, Feißt M, Seitz J, Hassel JC, Mayer L, Matthies LM, Schumann A, Hennigs A, Heil J, Sohn C, Jaeger D, Schneeweiss A, Marmé F.

Breast Cancer Res Treat. 2019 Jan;173(1):135-143. doi: 10.1007/s10549-018-4983-8. Epub 2018 Sep 25.

PMID:
30255454
14.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

PMID:
30242316
15.

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

Buder-Bakhaya K, Hassel JC.

Front Immunol. 2018 Jun 28;9:1474. doi: 10.3389/fimmu.2018.01474. eCollection 2018. Review.

16.

Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT.

Sachpekidis C, Anwar H, Winkler JK, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Cancer Immunol Immunother. 2018 Aug;67(8):1261-1270. doi: 10.1007/s00262-018-2183-3. Epub 2018 Jun 5.

PMID:
29872898
17.

Rituximab as a therapeutic option for patients with advanced melanoma.

Winkler JK, Schiller M, Bender C, Enk AH, Hassel JC.

Cancer Immunol Immunother. 2018 Jun;67(6):917-924. doi: 10.1007/s00262-018-2145-9. Epub 2018 Mar 7.

PMID:
29516155
18.

STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.

Machiraju D, Moll I, Gebhardt C, Sucker A, Buder-Bakhaya K, Schadendorf D, Hassel JC.

Melanoma Res. 2018 Jun;28(3):204-210. doi: 10.1097/CMR.0000000000000435.

PMID:
29485532
19.

The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.

Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. doi: 10.1007/s00259-018-3972-9. Epub 2018 Feb 24.

PMID:
29478079
20.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

21.

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.

Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D.

Eur J Cancer. 2018 Feb;90:122-129. doi: 10.1016/j.ejca.2017.12.001. Epub 2018 Jan 5.

PMID:
29306769
22.

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R; German Dermatooncology Group (DeCOG/ADO).

Cancer Med. 2018 Jan;7(1):95-104. doi: 10.1002/cam4.1267. Epub 2017 Dec 20.

23.

Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.

Sachpekidis C, Hassel JC, Dimitrakopoulou-Strauss A.

Hell J Nucl Med. 2017 Sep-Dec;20(3):251-253. doi: 10.1967/s002449910611. Epub 2017 Nov 27.

24.

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.

Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383. doi: 10.1007/s00259-017-3870-6. Epub 2017 Nov 10.

PMID:
29124281
25.

Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature.

Winkler JK, Gutzmer R, Bender C, Lang N, Zeier M, Enk AH, Hassel JC.

J Immunother. 2017 Nov/Dec;40(9):341-344. doi: 10.1097/CJI.0000000000000188. Review.

PMID:
29028789
26.

Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies.

Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz HM, Hassel JC.

Cancer Immunol Immunother. 2018 Feb;67(2):175-182. doi: 10.1007/s00262-017-2069-9. Epub 2017 Oct 10.

PMID:
29018908
27.

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe).

Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, Halama N, Dimitrakopoulou-Strauss A, Haefeli WE, Jäger D, Enk A, Utikal J, Umansky V.

Oncoimmunology. 2017 May 16;6(9):e1326440. doi: 10.1080/2162402X.2017.1326440. eCollection 2017.

28.

Spiny Keratoderma der Hand- und Fußflächen - einmal gesehen, nie wieder vergessen.

Gaiser MR, Hausser I, Hassel JC.

J Dtsch Dermatol Ges. 2017 Sep;15(9):938-940. doi: 10.1111/ddg.13313_g. No abstract available.

PMID:
28872249
29.

Spiny keratoderma of the palms and soles - once seen, never forgotten.

Gaiser MR, Hausser I, Hassel JC.

J Dtsch Dermatol Ges. 2017 Sep;15(9):939-941. doi: 10.1111/ddg.13313. No abstract available.

PMID:
28872240
30.

[Malignant melanoma : Current status].

Winkler JK, Buder-Bakhaya K, Dimitrakopoulou-Strauss A, Enk A, Hassel JC.

Radiologe. 2017 Oct;57(10):814-821. doi: 10.1007/s00117-017-0281-4. Review. German.

PMID:
28730266
31.

Liquid Biopsy: Value for Melanoma Therapy.

Buder-Bakhaya K, Machiraju D, Hassel JC.

Oncol Res Treat. 2017;40(7-8):430-434. doi: 10.1159/000478893. Epub 2017 Jul 19. No abstract available.

32.

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients.

Teramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, Tüting T, Ulrich C, Wollina U, Hassel JC, Gutzmer R, Goerdt S, Zouboulis C, Leiter U, Eigentler TK, Garbe C.

Br J Dermatol. 2018 Feb;178(2):443-451. doi: 10.1111/bjd.15803. Epub 2017 Dec 20.

PMID:
28707317
33.

Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib.

Winkler JK, Buder-Bakhaya K, Ellert E, Herpel E, Martens UM, Enk A, Hassel JC.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e31-e32. doi: 10.1111/jdv.14467. Epub 2017 Aug 2. No abstract available.

PMID:
28695986
34.

Radiosensibilisierung durch BRAF Inhibitoren.

Strobel SB, Pätzold S, Zimmer L, Jensen A, Enk A, Hassel JC.

J Dtsch Dermatol Ges. 2017 Jul;15(7):703-708. doi: 10.1111/ddg.12672_g.

PMID:
28677189
35.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.

J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3.

PMID:
28671856
36.

Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?

Bender C, Enk A, Gutzmer R, Hassel JC.

Cancer Med. 2017 Jul;6(7):1581-1586. doi: 10.1002/cam4.887. Epub 2017 Jun 21.

37.

Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.

Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, Hassel JC.

J Immunother. 2017 Sep;40(7):282-285. doi: 10.1097/CJI.0000000000000178.

PMID:
28604554
38.

Radiosensitization by BRAF inhibitors.

Strobel SB, Pätzold S, Zimmer L, Jensen A, Enk A, Hassel JC.

J Dtsch Dermatol Ges. 2017 Jul;15(7):703-708. doi: 10.1111/ddg.12672. Epub 2017 May 30.

PMID:
28557366
39.

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R.

Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18. Review.

PMID:
28550712
40.

Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.

Blasig H, Bender C, Hassel JC, Eigentler TK, Sachse MM, Hiernickel J, Koop A, Satzger I, Gutzmer R.

Melanoma Res. 2017 Aug;27(4):321-325. doi: 10.1097/CMR.0000000000000341.

PMID:
28257394
41.

Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients.

Winkler JK, Dimitrakopoulou-Strauss A, Sachpekidis C, Enk A, Hassel JC.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):e389-e391. doi: 10.1111/jdv.14193. Epub 2017 Mar 22. No abstract available.

PMID:
28256019
42.

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG).

Eur J Cancer. 2017 Apr;75:24-32. doi: 10.1016/j.ejca.2016.12.038. Epub 2017 Feb 16.

PMID:
28214654
43.

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.

Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Höfer T, Trumpp A, Halama N, Hassel JC, Strobel O, Büchler M, Sahin U, Offringa R.

Oncoimmunology. 2016 Oct 7;5(12):e1240859. doi: 10.1080/2162402X.2016.1240859. eCollection 2016.

44.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD.

J Clin Oncol. 2017 Jan 10;35(2):226-235. Epub 2016 Nov 7.

45.

Exanthematous cutaneous spread of metastatic urothelial carcinoma in a 69-year-old man.

Salz M, Saborowski A, Toberer F, Enk AH, Hassel JC.

J Dtsch Dermatol Ges. 2016 Dec;14(12):1300-1302. doi: 10.1111/ddg.12717. No abstract available.

PMID:
27992145
46.

Exanthematisch aufgetretene kutane Metastasen eines Urothelkarzinoms bei einem 69-jährigen Patienten.

Salz M, Saborowski A, Toberer F, Enk AH, Hassel JC.

J Dtsch Dermatol Ges. 2016 Dec;14(12):1300-1302. doi: 10.1111/ddg.12717_g. No abstract available.

PMID:
27992131
47.

PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.

Schneiderbauer R, Schneiderbauer M, Wick W, Enk AH, Haenssle HA, Hassel JC.

Acta Derm Venereol. 2017 Mar 10;97(3):395-396. doi: 10.2340/00015555-2548. No abstract available.

48.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD.

Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16.

49.

PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.

Winkler JK, Bender C, Kratochwil C, Enk A, Hassel JC.

Br J Dermatol. 2017 Jan;176(1):216-219. doi: 10.1111/bjd.14632. Epub 2016 Oct 23.

PMID:
27038231
50.

Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.

Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, Enk A, Hassel JC.

Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17. No abstract available.

PMID:
27061826

Supplemental Content

Loading ...
Support Center